BeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing

Bulletin Express

08/14

BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.

The forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.

Corporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1193188148"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1193188148\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1193188148?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-14 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193188148","market":"us","top_or_hot":-1,"title":"BeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing","media":"Bulletin Express","content":"<p>BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.</p>\n<p>The forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.</p>\n<p>Corporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-08-14 17:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.</p>\n<p>The forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.</p>\n<p>Corporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百濟神州","start_time":0,"source_url":"","article_id":"1193188148","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193188148","pubTimestamp":1786699592,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"BeOne Medicines 计划于 2026 年 8 月 26 日召开审计委员会会议，批准 26 年上半年业绩，与之前的美国文件一致","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.\nThe forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.\nCorporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}